A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer.
- 1 July 2003
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 56 (4) , 1073-1078
- https://doi.org/10.1016/s0360-3016(03)00206-2
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Practical application of biochemical failure definitions: what to do and when to do itInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Definitions of biochemical failure in prostate cancer following radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Patterns and fate of PSA bouncing following 3D-CRTInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustnessInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate Cancer: The relationship between nadir level and disease-free survivalJournal of Urology, 1996
- Age- and race-specific reference ranges for prostate-specific antigen from a large community-based studyUrology, 1996
- The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation TherapyJournal of Urology, 1991